Fox Chase Cancer Center News

PHILADELPHIA (February 5, 2021)—Researchers at Fox Chase Cancer Center have found that patients with signet-ring cell gastric carcinoma (SRGC) and non-signet-ring cell gastric carcinoma (NSRGC), two variants of stomach cancer, have better overall survival when they are treated at academic centers compared to community centers.

PHILADELPHIA (February 2, 2021) – New research out of Fox Chase Cancer Center has shed light on how an important type of T cell–gamma delta T cells–develop and are assigned their effector function. 

PHILADELPHIA (February 1, 2021)—Fox Chase Cancer Center will host a virtual symposium on cancer epigenetics on March 2 that will explore discoveries related to epigenetic mechanisms of tumorigenesis and novel therapies to better target cancer.  

PHILADELPHIA (January 26, 2021) – Fox Chase Cancer Center announces the hiring of Cihangir Duy, PhD, MS, who has joined the Cancer Signaling and Epigenetics Program as an assistant professor.

PHILADELPHIA (January 19, 2021)—Elizabeth Plimack, MD, MS, professor in the Department of Hematology/Oncology and chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has been appointed chair of the Scientific Advisory Board (SAB) for the Bladder Cancer Advocacy Network (BCAN).

PHILADELPHIA (January 11, 2021) – Fox Chase Cancer Center is pleased to announce the addition of Joel Helmke, MSHP, FACHE, to its senior leadership team as chief operating officer (COO). Helmke’s tenure will begin on February 1, 2021.

PHILADELPHIA (January 11, 2021) – Fox Chase Cancer Center is pleased to announce the recruitment of Anna Liza Rodriguez, MSN, MHA, RN, OCN®, NEA-BC, as chief nursing officer (CNO) and vice president of nursing and patient services. Rodriguez’s start date is February 1, 2021.

PHILADELPHIA (January 5, 2021) – Joshua E. Meyer, MD, associate professor in the Department of Radiation Oncology at Fox Chase Cancer Center, has been awarded a grant to investigate the role of local consolidative therapy with radiation in the second-line treatment of metastatic colorectal cancer.